A patient is taking ezetimibe (Zetia) and asks the nurse how it works. The nurse should explain that Ezetimibe does what?

Ezetimibe (Zetia) is a unique antihyperlipidemic agent that works differently from statins and bile acid sequestrants. Its main action is to selectively block cholesterol absorption in the small intestine, thereby reducing the amount of cholesterol delivered to the liver. This decreases hepatic cholesterol stores and increases clearance of cholesterol from the blood, effectively lowering LDL levels.

Rationale for correct answer:
A. Inhibits absorption of dietary cholesterol in the intestines: Ezetimibe acts on the brush border of the small intestine to block the Niemann-Pick C1-Like 1 (NPC1L1) transporter, reducing cholesterol absorption from both dietary sources and bile. This results in lower serum LDL cholesterol without significantly affecting triglycerides or HDL.

Rationales for incorrect answers:
B. Binds with bile acids in the intestines to reduce LDL levels: This describes the mechanism of bile acid sequestrants (e.g., cholestyramine, colesevelam), not ezetimibe.
C. Inhibits HMG-CoA reductase, which is necessary for cholesterol production in the liver: This is the mechanism of statins (e.g., simvastatin, atorvastatin), not ezetimibe.
D. Forms insoluble complexes and reduces circulating cholesterol in the blood: This is a vague description that more closely fits bile acid sequestrants, not ezetimibe.

Take-home points:

• Ezetimibe blocks intestinal cholesterol absorption via the NPC1L1 transporter.
• It is often used alone or in combination with statins for better LDL reduction.
• Unlike statins, it does not inhibit liver cholesterol synthesis but complements their action.

Ezetimibe (Zetia) is a cholesterol absorption inhibitor that reduces intestinal absorption of cholesterol, often prescribed in combination with a statin such as simvastatin (Zocor) for clients with hyperlipidemia. While generally well tolerated, ezetimibe is contraindicated in clients with active liver disease, including hepatitis C, because both ezetimibe and statins can impair liver function.

Rationale for correct answer:
C. Active hepatitis C:
Clients with active liver disease should not take ezetimibe in combination with statins because of the increased risk of liver injury. Hepatitis C already compromises liver function, and adding medications that affect the liver can worsen hepatic inflammation and elevate liver enzymes. This contraindication is based on the high risk of hepatotoxicity when combining ezetimibe with simvastatin in the presence of preexisting liver disease.

Rationales for incorrect answers:

A. History of severe constipation:
Constipation is not a contraindication for ezetimibe. Unlike bile acid sequestrants, ezetimibe does not cause significant gastrointestinal issues and has no direct link to worsening constipation.

B. History of hypertension:
Ezetimibe does not adversely affect blood pressure regulation. Clients with hypertension can safely use the medication alongside their antihypertensive therapy.

D. Type 2 diabetes mellitus:
Ezetimibe is not contraindicated in diabetes and can actually be beneficial since lowering cholesterol reduces cardiovascular risk, which is elevated in diabetic clients. No harmful interaction exists between ezetimibe and antidiabetic medications.

Take-home points:

• Active liver disease, such as hepatitis C, is a contraindication to ezetimibe use, especially when combined with statins.
• Ezetimibe is safe for clients with hypertension, diabetes, or constipation.
• Monitoring of liver enzymes is essential when prescribing cholesterol-lowering medications.